Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC.

Br J Haematol. 1998 Jul;102(2):509-15.

PMID:
9695966
2.

A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.

Clin Cancer Res. 1999 Sep;5(9):2392-8.

3.

A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES.

Blood. 1996 Aug 15;88(4):1188-97.

4.
5.

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.

Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, et al.

Blood. 1992 Feb 1;79(3):576-85.

6.

Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.

Shah SA, Lambert JM, Goldmacher VS, Esber HJ, Levin JL, Chungi V, Zutshi A, Braman GM, Ariniello PD, Taylor JA, et al.

Int J Immunopharmacol. 1993 Aug;15(6):723-36.

PMID:
7691767
7.

Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.

Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, et al.

Blood. 1993 May 1;81(9):2263-71.

8.

Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.

Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM.

Cancer Res. 1992 Aug 1;52(15):4200-7.

9.

Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.

Conry RM, Khazaeli MB, Saleh MN, Ghetie V, Vitetta ES, Liu T, LoBuglio AF.

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):231-41.

PMID:
8680651
10.
11.

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, et al.

J Clin Oncol. 1993 Apr;11(4):726-37.

PMID:
7683045
12.
13.

Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.

Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J.

Int J Cancer Suppl. 1994;8:57-9.

PMID:
7515030
14.

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.

Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J.

J Clin Oncol. 1997 Feb;15(2):723-34.

PMID:
9053498
15.

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.

Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA.

Cancer. 2003 Mar 15;97(6):1471-80.

16.

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.

Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al.

Blood. 1995 Jun 15;85(12):3457-65.

17.

Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.

Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.

Cancer Res. 1993 Mar 15;53(6):1360-7.

18.

Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.

Gonzalez R, Salem P, Bunn PA Jr, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA.

Mol Biother. 1991 Dec;3(4):192-6.

PMID:
1768370
19.

Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma.

Scadden DT, Schenkein DP, Bernstein Z, Luskey B, Doweiko J, Tulpule A, Levine AM.

Cancer. 1998 Dec 15;83(12):2580-7.

PMID:
9874466
20.

Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.

Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA.

Leuk Lymphoma. 1997 Jul;26(3-4):287-98.

PMID:
9322891

Supplemental Content

Support Center